No Data
Peijia Medical-B (09996.HK): Yu Zhiyun resigns as a non-executive director.
Grainews November 1st | Peijia Medical - B (09996.HK) announced that Yu Zhiyun has resigned as a non-executive director and member of the board of directors' remuneration committee on November 1, 2024, with immediate effect. Yu Zhiyun resigned from his position to devote more time to other work matters. Yu Zhiyun will continue to serve as a consultant to the company.
Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.
"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.
Guangzhou Municipal Party Committee Financial Office: Promote biomedical enterprises to go public.
Guangzhou Municipal Party Committee Deputy Director of the Financial Office, Wen Keyin, stated at a press conference that next steps will continue to create a favorable environment for venture capital development, nurture and strengthen patient capital, guide venture capital institutions to accurately meet the financing needs of biomedical enterprises; focus on the growth characteristics and financing needs of biomedical enterprises, carry out efficient incubation, production-financing matching, and listing cultivation work; continue to promote the integration of insurance institutions in Guangzhou with the characteristics of the biomedical industry, increase research and development efforts for medical instruments, biomedical products, etc. Specific measures include guiding venture capital and venture capital to support the long-term development of the biomedical industry, and increasing support for biomedical
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
Biomedical stocks are performing strongly, with Lai Kai Medical (02105) rising by 26.26%. Institutions point out that the valuation of the sector has reached historical lows, still with further room for recovery.
King Wus Financial News | The biopharmaceutical sector has shown strong performance, with Lai Kais pharmaceutical (02105) up 26.26%, Amy Pharmaceutical (06660) up 19.76%, Yimingonco (01541) up 7.04%, Hansoh Pharma (03692) up 6.4%, HutchMed (China) (00013) up 6.91%, Peijia Medical (09996) up 5.75%, Akeso (09926) up 5.77%. Bocom Intl indicated that the tenth batch of pharmaceutical national procurement volume documents show historically high thresholds and the highest proportion of injections, anticipating exceptionally intense competition.
There is no limit on price fluctuation, new stocks are being speculated! The pioneer of ultrasound submits an application for registration on the gem.
Cumulative dividends exceed 0.3 billion over 4 years.
No Data
No Data